Canaccord Genuity Reiterates Hold on MAKO Surgical (MAKO)
Other equities research analysts have also recently issued reports about the stock. Analysts at Mizuho downgraded shares of MAKO Surgical from a “buy” rating to a “neutral” rating in a research note to investors on Tuesday. They now have a $30.00 price target on the stock, down previously from $54.00. Separately, analysts at William Blair downgraded shares of MAKO Surgical from an “outperform” rating to a “market perform” rating in a research note to investors on Tuesday. Finally, analysts at Oppenheimer (NYSE: OPY) initiated coverage on shares of MAKO Surgical in a research note to investors on Thursday, April 12nd. They set a “market perform” rating on the stock.
Shares of MAKO Surgical opened at 26.27 on Tuesday. MAKO Surgical has a one year low of $21.40 and a one year high of $45.15. The company’s market cap is $1.114 billion.
MAKO Surgical last issued its quarterly earnings data on Monday, May 7th. The company reported ($0.28) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.20) by $0.08. The company’s revenue for the quarter was up 50.7% on a year-over-year basis. Analysts expect that MAKO Surgical will post $-0.12 EPS next quarter.
MAKO Surgical Corp. (MAKO) is a medical device company that markets its advanced robotic arm solution and orthopedic implants for minimally invasive orthopedic knee procedures.